Latest Period
Q1 2026
Security Snapshot
Cidara Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CDTX) Institutional Ownership
CUSIP: 171757206
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$221.38
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- CDTX
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 0
- Total 13F value
- $0
- Share change
- -30,710,724
- Value change
- -$6,780,975,675
- Number of holders
- 0
- Shares outstanding
- 32,142,857
- SEC-reported price per share
- $221.38
- Insider filing price
- $221.38
Latest holder snapshot
4 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CDTX - Cidara Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 171757206.
- 0 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 249 to 0 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $7,354,554,679 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 0 institutions filings for Q1 2026.
Security key
171757206
Latest holder period
Q1 2026
13F holders
0
13D/G owners
8
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 171757206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
CDTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 6.4% | $443,369,062 | 2,007,193 | The Vanguard Group | 31 Dec 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 4.4% | -16% | $113,871,586 | -$21,545,460 | 1,189,165 | -16% | BVF PARTNERS L P/IL | 15 Oct 2025 |
| BlackRock, Inc. | 4.6% | -15% | $111,424,214 | +$5,356,584 | 1,163,607 | +5.1% | BlackRock, Inc. | 30 Sep 2025 |
| Adage Capital Management, L.P. | 5% | -45% | $55,594,000 | +$5,559,400 | 1,100,000 | +11% | Adage Capital Management, L.P. | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP | 3.3% | -38% | $92,041,065 | -$16,034,916 | 961,164 | -15% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 3.2% | -67% | $32,299,508 | -$23,243,750 | 639,088 | -42% | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 |
| Commodore Capital LP | 2% | -58% | $56,019,600 | -$56,498,400 | 585,000 | -50% | Commodore Capital LP | 30 Sep 2025 |
| Point72 Asset Management, L.P. | 1.4% | -80% | $99,621,000 | -$249,731,915 | 450,000 | -71% | Point72 Asset Management, L.P. | 31 Dec 2025 |
As of 31 Mar 2026, 0 institutional investors reported holding 0 shares of Cidara Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CDTX). This represents 0% of the company’s total 32,142,857 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$6,780,975,675 | $221.38 | 0 |
| 2025 Q4 | 33,307,397 | $7,354,554,679 | +$1,490,730,425 | $220.89 | 249 |
| 2025 Q3 | 32,486,735 | $3,110,319,924 | +$679,666,083 | $95.76 | 167 |
| 2025 Q2 | 25,911,048 | $1,262,611,204 | +$803,273,260 | $48.71 | 106 |
| 2025 Q1 | 9,559,359 | $205,909,478 | +$57,592,846 | $21.54 | 45 |
| 2024 Q4 | 6,873,669 | $183,637,032 | +$100,865,295 | $26.88 | 40 |
| 2024 Q3 | 3,308,428 | $35,565,026 | +$20,361,776 | $10.75 | 27 |
| 2024 Q2 | 1,412,361 | $16,863,937 | +$16,863,734 | $11.94 | 25 |